Bladder cancer
Molecular diagnostics in the era of targeted therapies for mUCa

Farid (65 years old)

Farid, 65 years old, devotes his time to mentoring young entrepreneurs at a startup incubator, sharing his wisdom and experience to help them succeed. He initially presented with UCa of the bladder with bone and lymph node metastases and was treated with 6 cycles of gemcitabine + cisplatin. After progression with new bone metastases, he received pembrolizumab, but the treatment was stopped after 10 cycles due to grade 4 immune-related colitis.

Assessment summary:

  • ECOG PS: 1
  • Peripheral neuropathy: grade 1 due to prior cisplatin
  • No hearing impairment
  • GFR: 70 ml/min
  • Medical history: mild hypertension, hyperthyroidism
  • Lymph node biopsy testing results: FGFR3 wild type

After complete recovery from the immune-related colitis, the patient shows disease progression.

Which of the following treatment options would you choose for this patient?